The geriatric mania asenapine study (GeMS)

• There is a paucity of studies on elderly mania.
• Twenty-five elderly manic patients completed a 3-weeks study of asenapine treatment.
• YMRS score decreased significantly from baseline.
• Adverse events occurred in 9/34 (26%) patients.
• Asenapine efficacy in the elderly is supported.

RationalePopulation aging results in growing numbers of psychiatric disorders among older patients. Yet, there is a paucity of studies on elderly mania.ObjectiveTo evaluate the effect of asenapine on older manic inpatients.MethodsThirty-four elderly patients suffering from a manic episode, mean age 67.2 years were enrolled in an open-label 3-weeks study of asenapine treatment. Inclusion criteria: (1) DSM-IV criteria for manic episode (2) age above 60 years, (3) episode severity necessitating inpatient treatment, (4) Young Mania Rating Scale (YMRS) score at baseline >20, and (5) no prior asenapine treatment. Participants were prescribed asenapine 5 mg BID for 3 days and then dose increased to 10 mg BID till day 21 (study completion).ResultsTwenty-five patients completed the study. YMRS score decreased from a baseline mean of 27.0 ± 8.8 to 13.3 ± 12.0 at the end of the study (p < 0.001). Fourteen patients (56% of completers) achieved remission (YMRS score < 12). MADRS score decreased from a baseline mean of 7.6 ± 5.6 to 4.4 + 5.1 at the end of the study (p < 0.05); low baseline score should be noted. Sleep duration increased from a baseline median of 5.7 hours to 7.0 h at the end of the study (p < 0.05). Seven patients discontinued treatment due to adverse events. Two patients passed-away after study completion.ConclusionWe tentatively conclude that the efficacy of asenapine in reducing acute manic symptoms and achieving remission in the elderly is supported in this study. Caution is needed in patients with co-morbid physical conditions.